All Hands Meeting 2004 Title: Planned GCRC-BIRN Collaboration at BWH Jonathan Sacks, PhD.
-
Upload
ferdinand-jacobs -
Category
Documents
-
view
216 -
download
0
Transcript of All Hands Meeting 2004 Title: Planned GCRC-BIRN Collaboration at BWH Jonathan Sacks, PhD.
All Hands Meeting 2004
Title: Planned GCRC-BIRN Collaboration at BWH
Jonathan Sacks, PhD
Quantitative perfusion analysis
Methods - MRI protocol
• Absolute myocardial blood flows (MBF) (ml/min/g) at rest and during dipyridamole vasodilation were quantified by validated Fermi model deconvolution.
• Rest myocardial blood flow corrected for rate pressure product
• 6 segments at each endomyocardial and epimyocardial levels in each slice location
• Perfusion reserve (PR) = MBF during vasodilation MBF at rest
Abnormal quantitative FPMP = Segmental endomyocardial PR significantly lower than matching epimyocardial PR by paired student t-test (p < 0.05)
Scenario One: Cardiac MR
• Cardiac research is being done at GCRC
Under G. Adler M.D., PH.D., R. Kwong M.D. and others
• The study uses Cardiac MR to visualize blood perfusing through the heart. The purpose of the study is to determine whether treatment with an aldosterone receptor antagonist will improve myocardial perfusion in patients with diabetes mellitus.
• The image of the heart is divided into segments at each step in a time series. This enables blood perfusion to be visualized through time on each segment
Scenario One: Cardiac MR
• The Surgical Planning Lab (SPL) at BWH has over many years developed a set of tools for visualizing and analyzing MR images of the human brain and other organs. SPL is a participating site for both Morphometry and Function BIRN.
• These techniques provide superior resolution of MR images and many of them are automatic or semi-automatic
• If the techniques developed at SPL are applied to the study of blood perfusion in the cardiac study, very substantial gains in resolution and efficiency of computation are realized in comparison with current Cardiac MR
Scenario One: Cardiac MR
• One of the key requirements for tracking perfusion through a time series is registration of elements of the series with a baseline (the ‘first’ time slice)
• SPL has developed several registration techniques which are so accurate that it will be possible to track blood perfusion through a single voxel
• Segmentation using level sets, followed by ICPRegistration using non-linear warpingSpatio-temporal filtering
Scenario One: Cardiac MR
Alignment of anatomical models, MRI data and functional data from the CARTO system. Depicted here is simulated CARTO data and deidentified preoperative MRI data where the red dots show the position of the CARTO data points. The initial misaligned data (left) and the registration
Scenario One: Cardiac MR
Figure 12. Ibrowser controller showing image intervals and controls for indexing and animating.
nameorder
visibilitycopy
deletehold
viewer FGviewer BG
animation & viewing
manual indexing
Figure 1. Generalized visualization and morphometric tools supporting FBIRN FLAC
QA spatialprocessing
activationdetection
datainspection morphometric
interactive,multi-modalityvisualization
report
Interactive visualization tools
DB
morphometricfunctionalgeneticclinicaldemographic …
validation,reliability testing,populationpooling
activation detector suite
…
Interactive query for knowledge discovery
Scenario One: Cardiac MR
fMRI AMPA Potentiator Study Design
Baseline
LY451395 (0.2 mg BID)
or Placebo
Scan 1 Scan 2 Scan 3
Week 0 Week 5 Week 9
ScreeningVisit
-7 to -9days
LY451395 (1.0 mg BID)
or Placebo
fMRI Block Design Paradigm
NovelFace-Name
Pairs
RepeatedFace-Name
Pairs
NovelFace-Name
Pairs
RepeatedFace-Name
Pairs
40s 25s5s 40s 25s 40s 40s25s 5s
+ + ++ +
Scenario 2: Alzheimer Study
LEAM fMRI
Thirteen AD subjects completed study with all three adequate fMRI scan sessions• Eight subjects on MGH Siemens 3T (Trio)• Five subjects on BWH GE 3T (long bore)
fMRI Block Design: Test-Retest Reliability in AD patient
Differences in prefrontal activation in LY451395 vs. placebo
Session 3 > Session 1 for Drug (n=4) > Placebo (n=9)
GCRC: Gail Adler, MD, PhD
Reisa Sperling
Ray Kwong, MD
Joe Ronda, MS
Surgical Planning Lab, BWH:
Ron Kikinis, MD
Steve Pieper, PhD
C.F. Westin, PhD
Wendy Plesniak, PhD
Acknowledgements